



LUNDS
UNIVERSITET

Pharmacological models - How to improve them?

Ylva Wahlquist
Friday Seminar 3 Sep 2021





Contents

- ▶ Background and motivation
- ▶ Pharmacokinetic-Pharmacodynamic (PKPD) model
- ▶ Simulated example
- ▶ Identifiability of the PKPD model
- ▶ Ongoing work: Population model



Background




Figure: A schematic overview of open-loop anesthesia where the depth of consciousness is measured with EEG.



Motivation

Variability between individuals in the response to anesthetic drugs.




Figure: Simulated effect y for four patients with the same input.



PKPD model




Figure: PKPD model structure describing the relationship between drug infusion rate and clinical effect.



Simulated example




Figure: *Top:* Simulated true effect y^0 (black) and noise-corrupted observation y (gray). *Bottom:* Propofol infusion profile u .



Simulated example




Figure: *Top:* Simulated true effect y^0 (black) and noise-corrupted observation y (gray). *Bottom:* Propofol infusion profile u .

Problem: Poor input excitation!



Identifiability

Local identifiability:

Study the Fischer Information Matrix to find which parameter is least sensitive. Here, k_{12} the rate constant between the first and second compartment was the least sensitive.



Identifiability

Local identifiability:

Study the Fischer Information Matrix to find which parameter is least sensitive. Here, k_{12} the rate constant between the first and second compartment was the least sensitive.

Global identifiability:

By fixing each parameter – one at a time –, to a value that was off by a factor 100 it was possible to investigate how well the remaining parameters could compensate for this. Most parameters could be compensated for by the others.



Identifiability




Figure: Simulated true effect y (black). The green curve (not visible) show model output $g^o(u, \theta)$ where all parameters have been optimized with k_{13} fixed with to a factor 100 times its true value.



Identifiability




Figure: Simulated true effect y (black). The green and pink curve show model output $g^o(u, \theta)$ where all parameters have been optimized with k_{13} and γ , respectively, fixed with to a factor 100 times its true value.



Pole-zero cancellation

The transfer function from input u to $z = C_e/EC_{50}$ (linear part of PKPD model)

$$G_{z, u}(s) = K \frac{(s + z_1)(s + z_2)}{(s + p_1)(s + p_2)(s + p_3)(s + k_{e0})}$$



Identifiability




Figure: Simulated true effect y (black) and the green curve (not visible) show model output $g^o(u, \theta)$ where all parameters have been optimized with k_{13} fixed with to a factor 100 times its true value.



Ongoing work: Population model




Figure: Population model with covariates as input and PKPD model as output.



Ongoing work: Population model




Figure: Population predictions vs observed BIS.¹

¹Eleveld, D., Colin, P., Absalom, A., and Struys, M. (2018). Pharmacokinetic– pharmacodynamic model for propofol for broad application in anaesthesia and sedation.



Ongoing work: Population model

Expression for one parameter of a population model used today:

$$Q_2 \text{ (litre/min)} = \theta_5 \left(\frac{V2}{V2_{\text{ref}}} \right)^{0.75} \left(1 + \theta_{16} \left(1 - \frac{\text{AGE} + 40\text{weeks}}{(\text{AGE} + 40\text{weeks}) + \theta_{14}} \right) \right)$$

where

$$V2(l) = \theta_2 \frac{\text{WGT}}{\text{WGT}_{\text{ref}}} \exp(\theta_{10} (\text{AGE} - \text{AGE}_{\text{ref}}))$$



Code

Code for replicating results in the paper “Identifiability of pharmacological models for onlien individualization” can be found at
<https://gitlab.control.lth.se/ylva/pkpdidentifiability>



Bode plots




Figure: Bode plots of the models in Fig. 5. See Fig. 5 for further specification of the individual models.